Delving into the Latest Updates on Artielle ImmunoTherapeutics, Inc. with Synapse

Overview

RTL1000 is a new agent that has not been previously tested in humans. It is thought that RTL may specifically control the abnormal immune response or attack against the insulation on the nerves that occurs in multiple sclerosis.
The purpose of this study is to evaluate the possible side effects of a single intravenous dose of RTL1000 in subjects with multiple sclerosis. Some subjects will also be asked to participate in one or both of two substudies, one to test blood samples to see how the body's immune system responds after administration of RTL1000, and the other to test blood samples to see how the body absorbs and eliminates the RTL1000.

Start Date01 Dec 2006

Sponsor / Collaborator

Artielle ImmunoTherapeutics, Inc.

100 Clinical Results associated with Artielle ImmunoTherapeutics, Inc.

Login to view more data

0 Patents (Medical) associated with Artielle ImmunoTherapeutics, Inc.

Login to view more data

100 Deals associated with Artielle ImmunoTherapeutics, Inc.

Login to view more data

100 Translational Medicine associated with Artielle ImmunoTherapeutics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 21 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data